OMS 1029
Alternative Names: anti-MASP-2 antibody; OMS-1029Latest Information Update: 24 Aug 2026
At a glance
- Originator Omeros Corporation
- Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action MASP2 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Wet age-related macular degeneration
Most Recent Events
- 24 Aug 2026 Phase-II clinical trials in Wet age-related macular degeneration (In volunteers) (Parenteral) (Omeros Corporation pipeline, August 2026)
- 23 Sep 2025 OMS 1029 is still in phase-I clinical development in Wet age related macular degeneration (In volunteers) in USA (IV) (SC) (Omeros Corporation pipeline, September 2025)
- 07 Aug 2024 Omeros Corporation plans a phase II trial for Wet age related macular degeneration